Immunological biomarkers: Catalysts for translational advances in autoimmune diabetes

S. T. Ahmed; E. Akirav; E. Bradshaw; J. Buckner; E. Mckinney; F. J. Quintana; F. Waldron-Lynch; J. Nepom

doi:10.1111/cei.12063

Immunological biomarkers: Catalysts for translational advances in autoimmune diabetes

S. T. Ahmed, E. Akirav, E. Bradshaw, J. Buckner, E. Mckinney, F. J. Quintana, F. Waldron-Lynch, J. Nepom

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In a recent workshop organized by the JDRF focused on the 'Identification and Utilization of Robust Biomarkers in Type1 Diabetes', leaders in the field of type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this paper, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.

Original language	English
Pages (from-to)	178-185
Number of pages	8
Journal	Clinical and Experimental Immunology
Volume	172
Issue number	2
DOIs	https://doi.org/10.1111/cei.12063
State	Published - May 2013
Externally published	Yes

Keywords

Autoimmunity
Diabetes
Peptide immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cei.12063

Cite this

@article{7f7e81cf33c046f6992163047b78ddc5,

title = "Immunological biomarkers: Catalysts for translational advances in autoimmune diabetes",

abstract = "In a recent workshop organized by the JDRF focused on the 'Identification and Utilization of Robust Biomarkers in Type1 Diabetes', leaders in the field of type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this paper, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.",

keywords = "Autoimmunity, Diabetes, Peptide immunotherapy",

author = "Ahmed, {S. T.} and E. Akirav and E. Bradshaw and J. Buckner and E. Mckinney and Quintana, {F. J.} and F. Waldron-Lynch and J. Nepom",

year = "2013",

month = may,

doi = "10.1111/cei.12063",

language = "English",

volume = "172",

pages = "178--185",

journal = "Clinical and Experimental Immunology",

issn = "0009-9104",

number = "2",

}

TY - JOUR

T1 - Immunological biomarkers

T2 - Catalysts for translational advances in autoimmune diabetes

AU - Ahmed, S. T.

AU - Akirav, E.

AU - Bradshaw, E.

AU - Buckner, J.

AU - Mckinney, E.

AU - Quintana, F. J.

AU - Waldron-Lynch, F.

AU - Nepom, J.

PY - 2013/5

Y1 - 2013/5

N2 - In a recent workshop organized by the JDRF focused on the 'Identification and Utilization of Robust Biomarkers in Type1 Diabetes', leaders in the field of type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this paper, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.

AB - In a recent workshop organized by the JDRF focused on the 'Identification and Utilization of Robust Biomarkers in Type1 Diabetes', leaders in the field of type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this paper, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.

KW - Autoimmunity

KW - Diabetes

KW - Peptide immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84876086248&partnerID=8YFLogxK

U2 - 10.1111/cei.12063

DO - 10.1111/cei.12063

M3 - Article

C2 - 23574315

AN - SCOPUS:84876086248

SN - 0009-9104

VL - 172

SP - 178

EP - 185

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

IS - 2

ER -

Immunological biomarkers: Catalysts for translational advances in autoimmune diabetes

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this